Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.
暂无分享,去创建一个
R. Levine | D. Gilliland | Benjamin H. Lee | G. Wernig | R. Okabe | T. Mercher | R. Levine
[1] H. Lodish,et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[2] E. Estey,et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. , 2005, Blood.
[3] H. Heimpel,et al. The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients. , 2005, Blood.
[4] D. Oscier,et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. , 2005, Blood.
[5] Stefan N Constantinescu,et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. , 2005, Nature.
[6] K. Kaushansky. On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. , 2005, Hematology. American Society of Hematology. Education Program.
[7] Mario Cazzola,et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.
[8] Sandra A. Moore,et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.
[9] P. Campbell,et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.
[10] J. Kutok,et al. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. , 2004, Blood.
[11] W. Hiddemann,et al. Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information , 2005, Annals of Hematology.
[12] S. Targan,et al. Enhancer Role of STAT5 in CD2 Activation of IFN-γ Gene Expression1 , 2004, The Journal of Immunology.
[13] S. Targan,et al. Enhancer role of STAT5 in CD2 activation of IFN-gamma gene expression. , 2004, Journal of immunology.
[14] F. Girodon,et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. , 2004, Haematologica.
[15] J. Jelinek,et al. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. , 2003, Blood.
[16] D. Gilliland,et al. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. , 2002, Blood.
[17] J. Aster,et al. Transformation of hematopoietic cell lines to growth‐factor independence and induction of a fatal myelo‐ and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes , 1998, The EMBO journal.
[18] A. Cumano,et al. Jak2 Deficiency Defines an EssentialDevelopmental Checkpoint in DefinitiveHematopoiesis , 1998, Cell.
[19] J. Marine,et al. Jak2 Is Essential for Signaling through a Variety of Cytokine Receptors , 1998, Cell.
[20] F. Barany,et al. Transcriptional analysis of the active X-chromosome in normal and clonal hematopoiesis. , 1993, Blood.
[21] C. Reid. The significance of endogenous erythroid colonies (EEC) in haematological disorders. , 1987, Blood reviews.
[22] A. Look,et al. Two-color flow cytometric measurement of DNA distributions of rat megakaryocytes in unfixed, unfractionated marrow cell suspensions. , 1984, Blood.
[23] J. Bryant,et al. Clonal origin and trisomy of chromosome 15 in murine B‐cell malignancies , 1980, International journal of cancer.
[24] J. Adamson,et al. Polycythemia vera: stem-cell and probable clonal origin of the disease. , 1976, The New England journal of medicine.
[25] Prchal Jf,et al. Letter: Bone-marrow responses in polycythemia vera. , 1974 .
[26] A. Axelrad,et al. Letter: Bone-marrow responses in polycythemia vera. , 1974, The New England journal of medicine.
[27] W. Dameshek. Editorial: Some Speculations on the Myeloproliferative Syndromes , 1951 .
[28] W. Dameshek. Some speculations on the myeloproliferative syndromes. , 1951, Blood.